Cancer

Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?

Read the plain language summary of an analysis of the PROSPER study looking at whether patient traits affect survival in people with advanced prostate cancer who are treated with enzalutamide compared to placebo.
Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?

This plain language summary provides an overview of a real-world study involving men with advanced prostate cancer using medical information from the Veterans Health Administration.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study

Understand the results of the PHERGain study looking at whether a type of imaging can identify people with HER2-positive early breast cancer who are more likely to benefit from treatment with trastuzumab and pertuzumab without the need for chemotherapy.
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

Read about the ongoing TALAPRO-2 study looking at the combination of talazoparib and enzalutamide as a first treatment in adult men with metastatic castration-resistant prostate cancer.
Plain language summary of outcomes in people treated for lung squamous cell cancer with afatinib after receiving pembrolizumab with chemotherapy

This new plain language summary from Future Oncology can help people understand if the treatment afatinib could be an option for people who have already been treated for metastatic squamous cell carcinoma of the lung with pembrolizumab plus chemotherapy.
Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugs

This plain language summary reports the findings of a recent review looking at the background and studies of different treatments for NRG1 fusion-positive cancers.
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial

Summary and patient perspectives of the ARASENS trial looking at treatment with darolutamide compared to placebo in combination with docetaxel and androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer.
Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer

This is plain language summary provides an overview of the HERO study looking at how well relugolix works, compared with leuprolide, in men with advanced prostate cancer.
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer

This new plain language summary explains the results of the JAVELIN Bladder 100 study, which looked at avelumab maintenance treatment in people with advanced urothelial cancer.
A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma

A new plain language summary discussing the results of a clinical study that looked at the use of two immunotherapy drugs, pembrolizumab and ipilimumab, for the treatment of advanced melanoma.
Plain language summary of publication: new information for the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer

A new plain language summary of a case series, which looked at how well a drug called afatinib worked in people who have a rare type of cancer called neuregulin-1 (also called NRG1) gene fusion-positive cancer.
Plain language summary of INSIGHT 2: a study to learn about the effects and safety of tepotinib plus osimertinib in patents with a type of non-small cell lung cancer

Read about the ongoing INSIGHT 2 study looking at the effects and safety of tepotinib combined with osimertinib, in patients with lung cancer that has stopped responding to osimertinib because of resistance.
Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients: a plain language summary

Read this plain language summary to understand how people from different ethnic groups respond differently to treatments for non-small cell lung cancer.
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer

The new plain language summary helps people understand the results of the ADAURA study of osimertinib in a type of non-small cell lung cancer.
Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study

Read the plain language summary discussing the result of the INVICTUS study looking at ripretinib as a potential treatment for advanced gastrointestinal stromal tumor.
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer

This plain language summary helps patients with untreated non-small cell lung cancer learn about the results of the CROWN study.
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

The latest plain language summary describes the findings of the ASCENT study looking at sacituzumab govitecan as a treatment for metastatic triple-negative breast cancer.
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer

The new plain language summary in Future Oncology helps patients understand the results of the GARNET study of dostarlimab in recurrent or advanced endometrial cancer.
Plain language summary describing the NeoADAURA study in non-small-cell lung cancer

Read the latest supplementary plain language summary published alongside an article in Future Oncology.
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study

Our latest plain language summary helps patients with HER2-positive breast cancer understand the results of the DESTINY-Breast01 study.
Plain language summary of the final results from the GioTag study

Plain language summary of the GioTag study now published in Future Oncology.
Plain language summary of article discussing race and ethnicity of participants in early-phase cancer studies

Discover the latest supplementary plain language summary published in Future Oncology
Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial

The latest plain language summary of publication (PLSP) published in Future Oncology provides a summary of the ARAMIS trial.
ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)

The first of it’s kind published in a peer-reviewed journal, this article published in Future Oncology provides a lay language summary of the ENLIVEN study.